Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지

Long-Term Expression of von Willebrand Factor by a VSV-G Pseudotyped Lentivirus Enhances the Functional Activity of Secreted B-Domain-deleted Coagulation Factor VIII

  • Park, Sang Won (School of Life Sciences and Biotechnology, Korea University) ;
  • Choi, Sang-Yun (School of Life Sciences and Biotechnology, Korea University)
  • Received : 2007.04.23
  • Accepted : 2007.05.02
  • Published : 2007.08.31
⟨ Previous Next ⟩

Abstract

von Willebrand factor (vWF) is a multimeric glycoprotein which functions within the coagulation system. It colocalizes with factor VIII (FVIII) by non-covalent interaction and alters its intracellular trafficking. vWF is also instrumental in maintaining the stability of secreted FVIII. The principal objective of this study was to generate a lentivirus-based vWF expression vector for gene therapy of hemophilia A. We inserted a vWF of 8.8 Kb into a lentiviral vector thereby producing VSV-G-pseudotyped vEx52. However, its titer was quite low, presumably because the length of vWF gene exceeds the size limit of the lentiviral vector. In order to overcome the low-titer, we concentrated the vEx52 and thus increased the efficiency of transduction approximately 6-fold with $1/100^{th}$ of the volume. However, as concentration requires an additional laborious step, we attempted to enhance the transduction efficiency by deleting exons 24-46 and 29-46 in pRex52 to construct pRex23 and pRex28, and in pvEx52, yielding pvEx23 and pvEx28, respectively. The transfected pRex52 had a profound effect on the activity of secreted FVIII, and this activity declined as domains of vWF were deleted. However, when the domain-deleted vWF-lentiviruses were transduced into K562 cells, the vEx28 increased the activity of the secreted FVIII compared to what was observed with vEx52. This result is probably due to higher efficiencies of transduction and expression while retaining the essential domains required for proper interaction with FVIII.

Keywords

Acknowledgement

Supported by : Korea University, Korea Hemophilia Foundation

References

  1. Burns, J., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.-K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037
  2. Chang, L. J. and He, J. (2001) Retroviral vectors for gene therapy of AIDS and cancer. Curr. Opin. Mol. Ther. 3. 468-475
  3. Chuah, M. K., Collen, D., and VandenDriessche, T. (2004) Clinical gene transfer studies for hemophilia A. Semin. Thromb. Hemost. 30, 249-256
  4. De Meyer, D. F., Vanhoorelbeke, K., Chuah, M. K., Pareyn, I., Gillijns, V., et al. (2006) Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 107, 4728-4736 https://doi.org/10.1182/blood-2005-09-3605
  5. Doering, C., Parker, E. T., Healey, J. F., Craddock, H. N., Barrow, R. T., et al. (2002) Expression and characterization of recombinant murine factor VIII. Thromb. Haemost. 88, 450-458 https://doi.org/10.1055/s-0037-1613237
  6. Eum, W. S., Jang, S. H., Kim, D. W., Choi, H. S., Choi, S. H., et al. (2005) Enhanced transduction of Cu, Zn-superoxide dismutase with HIV-1 Tat protein transduction domains at both termini. Mol. Cells 19, 191-197
  7. Fay, P. J., Coumans, J. V., and Walker, F. J. (1991) von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J. Biol. Chem. 266, 2172-2177
  8. Federici, A. B. (2003) The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 88, EREP02
  9. Gangadharan, B., Parker, E. T., Ide, L. M., Spencer, H. T., and Doering, C. B. (2006) High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 107, 3859-3864 https://doi.org/10.1182/blood-2005-12-4961
  10. Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., et al. (1999) Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 12, 10010-10018
  11. Kaufman, R. J., Pipe, S. W., Tagliavacca, L., Swaroop, M., and Moussalli, M. (1997) Biosynthesis, assembly and secretion of coagulation factor VIII. Blood 8, S3-14
  12. Kaufman, R. J., Wasley, L. C., and Dorner, A. J. (1988) Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 263, 6352-6362
  13. Keeney, S. and Cumming, A. M. (2001) The molecular biology of von Willebrand disease. Clin. Lab. Haematol. 23, 209-230 https://doi.org/10.1046/j.1365-2257.2001.00400.x
  14. Kohn, D. (2001) Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern. Med. 249, 379-390 https://doi.org/10.1046/j.1365-2796.2001.00803.x
  15. Lewis, P., Hensel, M., and Emerman, M. (1992) Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 11, 3053-3058
  16. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R. et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-269 https://doi.org/10.1126/science.272.5259.263
  17. Over, J., Sixma, J. J., Bruine, M. H., Trieschnigg, M. C., Vlooswijk, R. A., et al. (1978) Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J. Clin. Invest. 62, 223-234
  18. Park, S. W. and Choi, S. Y. (2004) A stable gene transfer system for hematopoietic progenitor cells from human bone marrow using pseudotyped retroviral vectors. Mol. Cells 17, 297-303
  19. Parolin, C., Taddeo, B., Palu, G., and Sodroski, J. (1996) Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 222, 415-422 https://doi.org/10.1006/viro.1996.0438
  20. Rosenberg, J. B., Foster, P. A., Kaufman, R. J., Vokac, E. A., Moussalli, M., et al. (1998) Intracellular trafficking of Factor VIII to von Willebrand factor storage granules. J. Clin. Invest. 101, 613-624 https://doi.org/10.1172/JCI1250
  21. Powell, J. S., Ragni, M. V., White, G. C. Lusher, J. M., Hillman- Wiseman, C., et al. (2003) Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 102, 2038-2045 https://doi.org/10.1182/blood-2003-01-0167
  22. Sadler, J. E. (1998) Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67, 395-424 https://doi.org/10.1146/annurev.biochem.67.1.395
  23. Sadler, J. E. and Davie, E. W. (1994) In the molecular basis of blood disease, Stamatoyannopoulos, G., Nienhuis, A. W., Majerus, P. W., and Varmus, H. (eds.), pp. 657-700, Philadelphia, WB Saunders
  24. Tuddenham, E. G., Lane, R. S., Rotblat, F., Johnson, A. J., Snape, T. J., et al. (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br. J. Haematol. 52, 259-267 https://doi.org/10.1111/j.1365-2141.1982.tb03888.x
  25. Yee, J., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J., et al. (1994) A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91, 9564-9568
  26. Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., et al. (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185 https://doi.org/10.1016/S0092-8674(00)80828-4